Quick Answer
BridgeBio Pharma, Inc. reported R&D Expense of $451.95 million for fiscal year 2025.
BridgeBio Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $451.95M | -10.8% |
| 2024 | $506.46M | +11.1% |
| 2023 | $455.71M | +14.1% |
| 2022 | $399.46M | -11.4% |
| 2021 | $451.02M | +33.8% |
| 2020 | $337.05M | +60.5% |
| 2019 | $209.95M | +49.9% |
| 2018 | $140.07M | +358.4% |
| 2017 | $30.56M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $112.87M | -6.3% | +1.5% |
| June 30, 2025 | $111.23M | -3.0% | -0.2% |
| March 31, 2025 | $111.43M | -21.0% | -7.5% |
| September 30, 2024 | $120.44M | -3.7% | +5.0% |
| June 30, 2024 | $114.69M | +6.7% | -18.6% |
| March 31, 2024 | $140.97M | +51.8% | +12.7% |
| September 30, 2023 | $125.14M | +35.3% | +16.4% |
| June 30, 2023 | $107.49M | -0.8% | +15.8% |
- BridgeBio Pharma, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, BridgeBio Pharma, Inc.’s r&d expense has grown by 1379.1% (from $30.56 million to $451.95 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: